

Bibliography (manuscripts)

1. Danchin N, Ferrieres J, Guenound M, Cattane S, Rushton-Smith SK, Greenlaw N, Ferrari R, Steg PG, on behalf of the CLARIFY Investigators. Management of outpatients in France with stable coronary artery disease. Findings from the prospective observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry. *Arch Cardiovasc Diseases* 2014;107(8-9):452-61.
2. Díez-Pérez A, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Gehlbach SH, Greenspan SL, Hooven FH, LaCroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Siris ES, Wyman A, Rushton-Smith SK, Watts NB, for the GLOW Investigators. Risk Factors for Treatment Failure with Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW). *JBMR* 2013. doi: 10.1002/jbmr.2023.
3. Huang W, Anderson FA, Rushton-Smith SK, Cohen AT. Impact of Thromboprophylaxis Across the US Acute Care Setting. *PLoS One* 2015. DOI: 10.1371/journal.pone.0121429
4. Kakkar AJ, Rushton-Smith S. Introduction of international research facilities. The Thrombosis Research Institute. *Int Rev Thrombosis* 2011;6(4).
5. Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GYH, Mantovani LG, Turpie AGG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FWA, for the GARFIELD Registry Investigators. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. *PLoS One* 2013;8(5):e63479.
6. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, and Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). *Am Heart J* 2012;163:13-19 e1.
7. Kakkar AK, Rushton-Smith S. Venous thromboembolism pharmacologic prophylaxis after major surgery-are we doing well or not well enough? *Ann Surg* 2011;253(2):215-20
8. Kakkar AK, Rushton-Smith SK. Incidence of venous thromboembolism in orthopedic surgery. In: Llau JV, ed. *Thromboembolism in Orthopedic Surgery*. London: Springer; 2013:11-18.
9. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Jansky P, Mahmeed WA, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK, for the G-AFI. Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation? The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes* 2015.
10. Sabouret P, Bricard M, Hermann M-A, Cotté F-E, Leyla Deret-Bixio L, Rushton-Smith S. Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. *Arch Cardiovasc Dis* 2015 (in press).
11. Sabouret P*, Rushton-Smith SK*, Kerneis M, Silvain J, Collet JP, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. *Eur Heart J – CV Pharmacother* 2015 (in press). DOI: <http://dx.doi.org/10.1093/ehjcvp/pvv015>
*Joint first authors
12. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, Sadiq I, Kasper R, Rushton-Mellor SK, Anderson FA. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). *Am J Cardiol* 2002;90:358-363.
13. Vuylsteke A, Vincent JL, Payen de La Garanderie D, Anderson FA, Emery L, Wyman A, Rushton-Smith S, and Gore JM. Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hypertension (Euro-STAT). *Crit Care* 2011;15:R271.
14. Whitfield HN, Rushton-Mellor, SK. Definition of dysuria – reply. *Br J Urol* 1994;74(4):534.

Bibliography (abstracts)

1. Bassand J-PL, Rushton-Smith S, Camm AJ, Goldhaber SZ, Goto S, Haas S, Mueller I, Turpie AGG, Kakkar A, for the GARFIELD Investigators. Atrial Fibrillation Treatment Paradox: Characteristics of and First-Year Events in Patients Not Treated with Vitamin K antagonists Compared to Treated Patients. The GARFIELD Registry. *JACC* 2013;61(10):E379
2. Bassand JP, Mueller I, Mantovani LG, Haas S, Goldhaber SZ, Goto S, Lip GYH, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. Antithrombotic treatment patterns for stroke prevention in relation to age: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD) Evaluation. *Eur Heart J* 2012;33 (Abstract suppl):52-53.
3. Berge E, Atar D, Le Heuzey J-Y, Connolly S, Fitzmaurice DA, Camm AJ, Jansky P, Rushton-Smith SK, Kayani G, Kakkar AK. Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD Registry. ESC, 31 August 2013.
4. Camm AJ, Turpie AGG, Goto S, Stepinska J, Le Heuzey J-Y, Misselwitz F, Corbalan R, Rushton-Smith SK, Kayani G, Kakkar AK. One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD Registry. ESC, 3 Sept 2013.
5. Goto S, Lip GYH, Goldhaber SZ, Verheugt FWA, Bassand JP, Turpie AGG, Mueller I, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. Impact of renal function on use of antithrombotic therapy in atrial fibrillation: real-world perspective from the global anticoagulant registry in the FIELD. *Eur Heart J* 2012;33 (Abstract suppl):967-968.

6. Goto S, Mueller I, Fitzmaurice DA, Haas S, Lip GYH, Turpie AGG, Goldhaber SZ, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. Regional differences in the use of antithrombotic therapy for stroke prevention in atrial fibrillation: European and Asian insights from the Global Anticoagulant Registry in the FIELD (GARFIELD). *Eur Heart J* 2012;33 (Abstract suppl):685.
7. Goto S, Oh S, Bassand J-P, Gibbs H, Angchaisuksiri P, Rushton-Smith SK, Kayani G, Kakkar AK, Wilkinson P. Moderate-to-Severe Chronic Kidney Disease Associated With 1-Year All-Cause Mortality In Patients Newly Diagnosed With Non-Valvular Atrial Fibrillation. The Prospective International GARFIELD Registry. *AHA*, 18 November 2013.
8. Goto S, Oh S, Bassand JP, Gibbs H, Angchaisuksiri P, Rushton-Smith S, Kayani G, Wilkinson P, Kakkar A, for the GARFIELD Investigators. Moderate-To-Severe Chronic Kidney Disease Associated With 1-Year All-Cause Mortality In Patients Newly Diagnosed With Non-Valvular Atrial Fibrillation. The Prospective International GARFIELD Registry. *AHA* 2013
9. Goto S, Oh S, Cools F, Koretsune Y, Angchaisuksiri P, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights. *ESC*, 2 Sept 2013.
10. Hacke W, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Lip GYL, Mantovani L, Turpie AGG, Verheugt FWA, Misselwitz F, van Eickels M, Mueller I, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. Gap between evidence-based guidelines and provision of oral anticoagulant therapy among patients newly diagnosed with atrial fibrillation: Findings from Global Anticoagulant Registry in the FIELD. *AID539*.
11. Hacke W, Rushton-Smith S, Mueller I, Kakkar AK, for the GARFIELD Investigators. Characteristics and treatment of patients newly diagnosed with atrial fibrillation with versus without prior stroke: the global GARFIELD registry. *WSC*, 12 October 2012.
12. Kakkar AK, Bassand J-P, Goldhaber SZ, Agnelli G, Atar D, Berge E, Cools F, Haas S, Rushton-Smith SK, Hacke W. One-year outcomes in atrial fibrillation patients with versus without a previous stroke or transient ischaemic attack: findings from the international prospective GARFIELD Registry. *ESC*, 31 August 2013.
13. Le Heuzey J-Y, Goto S, Verheugt FWA, Cools F, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. Direct current conversion and clinical events at 1 year in patients with non-valvular atrial fibrillation. The Global Anticoagulant Registry in the FIELD (GARFIELD). *ESC*, 3 Sept 2013.
14. Lip G, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Verheugt FWA, Turpie AGG, Mueller I, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. Inappropriate utilization of Anticoagulation in Patients With Atrial Fibrillation: The Global Anticoagulant Registry in the FIELD (GARFIELD) Registry. *2012 J Am Coll Cardiol*; A1236-167.
15. Lip GYH, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Mueller I, Kakkar AK, for the GARFIELD Investigators. Gender differences in use of antithrombotic therapy in atrial fibrillation: real-world perspective from the Global Anticoagulant Registry in the FIELD (GARFIELD). *Eur Heart J* 2012;33 (Abstract suppl):58.
16. Lip GYH, Rushton-Smith SK, Goto S, Verheugt FWA, Goldhaber SZ, Haas S, Bassand JP, Mueller I, Kakkar AK, for the GARFIELD Investigators. Patterns of antithrombotic therapy and type of atrial fibrillation: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD). *Eur Heart J* 2012;33 (Abstract suppl):54.
17. Mantovani M, Mueller I, Bassand JP, Fitzmaurice D, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Rushton-Smith S, Kakkar AK; for the GARFIELD Investigators. Outcomes and Quality of Anticoagulant Control in Patients Newly Diagnosed with Non-valvular Atrial Fibrillation: Insights from the Worldwide GARFIELD Registry. *AHA* 2012.
18. Sanchez Diaz CJ, Goto S, Misselwitz F, Ambrosio G, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. One-year outcomes in atrial fibrillation patients with versus without coronary artery disease. The prospective Global Anticoagulant Registry in the FIELD (GARFIELD). *ESC*, 2 Sept 2013.
19. Turpie AGG, Camm AJ, Goto S, Stepinska J, Le Heuzey J-Y, Misselwitz F, Corbalan R, Rushton-Smith SK, Kayani G, Kakkar AK. Twelve-month outcomes in paroxysmal versus permanent atrial fibrillation: data from the prospective, international GARFIELD Registry. *ESC*, 2 Sept 2013.
20. Verheugt FWA, Bassand JP, Turpie AGG, Fitzmaurice DA, Haas S, Goto S, Lip GYH, Mueller I, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. Antithrombotic therapy for stroke prevention in patients with newly diagnosed atrial fibrillation and a history of acute coronary syndrome: the Global Anticoagulant Registry in the FIELD (GARFIELD). *Eur Heart J* 2012;33 (Abstract suppl):1081.
21. Verheugt FWA, Goldhaber SZ, Atar D, Camm AJ, Ambrosio G, Jansky P, Stepinska J, Rushton-Smith SK, Kayani G, Kakkar AK. Outcomes at 1 year in atrial fibrillation patients with versus without an acute coronary syndrome: insights from the prospective GARFIELD Registry. *ESC*, 2 Sept 2013.